The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future

Table 2

Characteristics of main trials on Spondyloarthritis-related anterior acute uveitis treated with biological DMARDs.

Reference	Study design	Diagnosis	Number of patients	Drug	Outcomes
Dobner BC 2013 [4]	Observational, retrospective, multicentric	SpA	60	ADA	Improvement criteria of visual activity and steroid sparing
van Denderen JC 2014 [5]	Observational, prospective	AS	71	ADA	Number of flares before and after drug treatment
Rudwaleit M 2009 [6]	Prospective open-label study	AS	274	ADA	Number of AAU flares
Hernandez MV 2016 [7]	Observational, multicentric, retrospective	SpA	14	CZP	Visual acuity
Yazgan S 2016 [8]	Observational, retrospective	AS	12	GOL	Steroid sparing, visual acuity and number of flares
Calvo-Río V 2016 [9]	Observational, prospective	SpA	15	GOL	Visual acuity
Faez S 2013 [10]	Retrospective case series	SpA	3	GOL	Visual acuity
Kim M 2016 [11]	Retrospective cohort study	AS	143	ADA, IFX, ETN	Number of flares and reduction in systemic medication
Wendling D 2014 [12]	Retrospective, cohort study	AS	2115	IFX, ADA, ETN	Risk of developing AAU
Lie E 2017 [13]	Observational, retrospective	AS	1365	IFX, ADA, ETN	AAU incidence before and after treatment

ADA: adalimumab; IFX: infliximab; ETN: etanercept; GOL: golimumab; CZP: certolizumab Pegol; AAU: acute anterior uveitis; SpA: Spondyloarthritis; AS: Ankylosing spondylitis.
In this study authors considered uveitis in general; however AAU were in 83.3% of patients.
In this study authors considered uveitis in general; however AAU were the majority of cases: 88% of patients in IFX group, 97% in ADA, and 63.2% in ETN.